Review of three new agents that target angiogenesis, matrix metalloproteinases, and cyclin-dependent kinases

Cancer Control

Volumn 6, Issue 5, 1999, Pages 459-465

  Lush, R M ^a   Rudek, M A ^a   Figg, W D ^a  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; CYCLIN DEPENDENT KINASE; ENDOSTATIN; FLAVOPIRIDOL; MARIMASTAT; MATRIX METALLOPROTEINASE; METALLOPROTEINASE INHIBITOR;

ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; DRUG SCREENING; HUMAN; LUPUS ERYTHEMATOSUS; PHOTOSENSITIVITY DISORDER;

EID: 0032751302     PISSN: 10732748     EISSN: None     Source Type: Journal    
DOI: 10.1177/107327489900600503     Document Type: Article

References (65)